Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 98 | NANETS2023 | Next issue

NANETS 2023

Abstracts

Clinical – Chemo/SSA/Biologics

Previous section
Basic Science
Table of contents
Next section
Clinical – Nuclear Medicine/Interventional Radiology/Imaging

ea0098c1 | Clinical – Chemo/SSA/Biologics

Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients living with metastatic neuroendocrine tumors

ea0098c2 | Clinical – Chemo/SSA/Biologics

Neuroendocrine tumor metastatic to breast: case report and review of the literature

ea0098c3 | Clinical – Chemo/SSA/Biologics

Real-world evidence of lenvatinib use for treatment of metastatic neuroendocrine neoplasms

ea0098c4 | Clinical – Chemo/SSA/Biologics

Results from a Phase II study of nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil (5-FU)/leucovorin in refractory advanced high-grade neuroendocrine cancer (HG-NEC)

ea0098c5 | Clinical – Chemo/SSA/Biologics

A phase 2 clinical trial of cabozantinib in patients with unresectable and progressive metastatic pheochromocytoma or paraganglioma: The NATALIE trial

ea0098c6 | Clinical – Chemo/SSA/Biologics

The role of somatostatin analogue maintenance therapy in refractory metastatic neuroendocrine tumors (NETs): comparative analysis

ea0098c7 | Clinical – Chemo/SSA/Biologics

A phase II clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms (NEN): updated overall survival data

ea0098c8 | Clinical – Chemo/SSA/Biologics

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of oral paltusotine, a small-molecule, selective somatostatin receptor subtype 2 agonist

ea0098c9 | Clinical – Chemo/SSA/Biologics

Anti-apoptosis as a therapeutic strategy in Neuroendocrine neoplasms (NEN): A case report

ea0098c10 | Clinical – Chemo/SSA/Biologics

An ongoing phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas

ea0098c11 | Clinical – Chemo/SSA/Biologics

Transformation of low-intermediate grade neuroendocrine tumors into high grade morphology

ea0098c12 | Clinical – Chemo/SSA/Biologics

Real world use of virtual care for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

ea0098c13 | Clinical – Chemo/SSA/Biologics

Clinical characteristics and molecular profiling of patients with pancreatic mixed acinar-neuroendocrine carcinoma

ea0098c14 | Clinical – Chemo/SSA/Biologics

Cabozantinib as salvage therapy for well differentiated grade 3 neuroendocrine tumors (G3 NETs)

ea0098c15 | Clinical – Chemo/SSA/Biologics

Phase II study of frontline maintenance rucaparib in combination with nivolumab in extensive stage small cell lung cancer

ea0098c16 | Clinical – Chemo/SSA/Biologics

Comparison of well-differentiated gastroenteropancreatic grade 3 neuroendocrine tumors (G3NETS): de novo and in the setting of apparent grade progression over time

ea0098c17 | Clinical – Chemo/SSA/Biologics

Argentinian registry of gastric neuroendocrine tumors: A closer look at type 1

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more